Jaguar Health, Inc. Logo

Jaguar Health, Inc.

Develops plant-based, non-opioid GI therapies for humans and animals.

JAGX | US

Overview

Corporate Details

ISIN(s):
US47010C6075
LEI:
Country:
United States of America
Address:
200 PINE STREET SUITE 400, 94104 SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on discovering, developing, and commercializing novel, plant-based prescription medicines to address urgent global health needs. The company's core focus is on sustainably derived, non-opioid therapies for gastrointestinal (GI) diseases in both humans and animals. Its product portfolio spans multiple stages of development, from preclinical to commercial approval. Key development programs include crofelemer for the preventative treatment of cancer therapy-related diarrhea and for rare disease indications such as short bowel syndrome.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jaguar Health, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jaguar Health, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Jaguar Health, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Immatics N.V. Logo
Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.
United States of America IMTX
Immix Biopharma, Inc. Logo
Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.
United States of America IMMX
IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America ICCC
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea 424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan 4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America IMVT

Talk to a Data Expert

Have a question? We'll get back to you promptly.